Every “retatrutide price” you can find in 2026 belongs to one of three categories: zero (clinical trials), illegitimate (gray-market vials), or speculative (post-approval projections). Anyone quoting a monthly price as if this were a purchasable medicine is selling something.
The only legitimate cost today: $0, in a trial
Phase 3 TRIUMPH participants receive the drug, monitoring, and medical oversight at no cost - that is how investigational medicines work. If cost is your constraint and eligibility fits, a trial isn't the discount option; it's the only option. How to actually get retatrutide covers eligibility and where trials recruit.
What gray-market sellers charge - and what you're actually buying
Research-chemical sites price “retatrutide” vials in the tens-to-hundreds of dollars per multi-milligram vial, which works out to a fraction of branded GLP-1 pricing. That discount is the product: no identity verification, no sterility assurance, no dosing format, no recourse, and explicit FDA warnings about exactly these products. Comparing that number to a pharmaceutical price is comparing a lottery ticket to a salary.
What approval-day pricing will probably look like
The honest forecast method is precedent, and the precedent is Lilly's own:
| Reference point | List price at launch | Self-pay reality |
|---|---|---|
| Zepbound (tirzepatide), 2023 | ≈ $1,060/month | $350-550/month via LillyDirect vials for some doses |
| Wegovy (semaglutide), 2021 | ≈ $1,350/month | Later ~$500/month self-pay programs |
| Retatrutide, 2027-28 (projection) | Likely ≥ Zepbound tier | Self-pay channels probable, following Lilly's playbook |
A drug that outperforms Zepbound in trials, from the same company, launching into proven demand, prices at a premium - that's not cynicism, it's every launch in this class so far. The wildcards are competition (survodutide, orforglipron, generics pressure on older GLP-1s) and the political environment around obesity-drug pricing.
The budgeting takeaway
If retatrutide fits your future plans, the rational 2026 move isn't finding a cheaper vial - it's either trial eligibility now, or budgeting for Zepbound-tier costs later while using the approved alternatives in the meantime if a clinician recommends one.
Frequently asked questions
How much does retatrutide cost per month?
There is no legitimate monthly price, because there is no legitimate product: retatrutide is unapproved and available only in trials, where participation is free. Numbers you see online are gray-market vial prices for unverifiable products - not a price for retatrutide.
What will retatrutide cost after FDA approval?
Unknown, but the precedent is clear: Lilly launched Zepbound (tirzepatide) around $1,060/month list, with savings programs and LillyDirect self-pay options near $350-550 for some doses. A higher-efficacy successor is unlikely to launch cheaper than its sibling.
Will insurance cover retatrutide?
That question starts existing on approval day. Coverage will likely mirror the GLP-1 pattern: variable commercial coverage, prior authorizations, and exclusions in many plans - the exact fight Zepbound and Wegovy patients know today.